High and low-risk febrile neutropenic patients

被引:2
|
作者
Blot, F [1 ]
Nitenberg, G [1 ]
机构
[1] Inst Gustave Roussy, Serv Reanimat Med Chirurgicale, F-94805 Villejuif, France
来源
PRESSE MEDICALE | 2004年 / 33卷 / 07期
关键词
D O I
10.1016/S0755-4982(04)98634-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Identification of low-risk patients These patients exhibit a low probability of dying (risk equal or lesser than 1%) and of developing major complications (risk to the order of 5%). A clinical model developed by Talcott et al. considers at low risk patients at home when the fever starts, without severe co-morbidity and in whom the neoplasia is under control. A prognostic score was established by the MASCC (Multinational Association for Supportive Care in Cancer); it is based on objectively weighted and selected variables. In comparaison, the Talcott's classification appears more restrictive (2.5-fold less patients at low risk) but also that it supplies greater safety Identification of high-risk patients All the severity scores used in intensive care have their limits. However, the repeated calculation of severity scores (at 48 and 72 hours) might lead to an improvement in their predictive value. The number of organ dysfunction could also be used because the latter provides supplementary clinical information and hence the development of organ dysfunction scores over the past few years. For febrile neutropenic patients other than in intensive care, the interest of the severity scores and organ dysfunction scores appears limited.
引用
收藏
页码:467 / 473
页数:7
相关论文
共 50 条
  • [1] Outpatient antibiotic treatment in low-risk febrile neutropenic cancer patients
    Escalante, CP
    Rubenstein, EB
    Rolston, KVI
    SUPPORTIVE CARE IN CANCER, 1996, 4 (05) : 358 - 363
  • [2] Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients
    Rolston, Kenneth V. I.
    Frisbee-Hume, Susan E.
    Patel, Shreyaskumar
    Manzullo, Ellen F.
    Benjamin, Robert S.
    SUPPORTIVE CARE IN CANCER, 2010, 18 (01) : 89 - 94
  • [3] Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients
    Kenneth V. I. Rolston
    Susan E. Frisbee-Hume
    Shreyaskumar Patel
    Ellen F. Manzullo
    Robert S. Benjamin
    Supportive Care in Cancer, 2010, 18 : 89 - 94
  • [4] OUTPATIENT TREATMENT OF FEBRILE EPISODES IN LOW-RISK NEUTROPENIC PATIENTS WITH CANCER
    RUBENSTEIN, EB
    ROLSTON, K
    BENJAMIN, RS
    LOEWY, J
    ESCALANTE, C
    MANZULLO, E
    HUGHES, P
    MORELAND, B
    FENDER, A
    KENNEDY, K
    HOLMES, F
    ELTING, L
    BODEY, GP
    CANCER, 1993, 71 (11) : 3640 - 3646
  • [5] Outpatient antibiotic therapy for febrile episodes in low-risk neutropenic patients with cancer
    Escalante, CP
    Rubenstein, EB
    Rolston, KVI
    CANCER INVESTIGATION, 1997, 15 (03) : 237 - 242
  • [6] Predictive Factors of Bacteremia in the Low-Risk Febrile Neutropenic Patient
    Ahn, S.
    Lee, Y.
    Lim, K.
    ANNALS OF EMERGENCY MEDICINE, 2011, 58 (04) : S277 - S278
  • [7] Early discharge of low-risk febrile neutropenic children and adolescents with cancer
    Aquino, VM
    Tkaczewski, I
    Buchanan, GR
    CLINICAL INFECTIOUS DISEASES, 1997, 25 (01) : 74 - 78
  • [8] Low-dose continuous-infusion ceftazidime monotherapy in low-risk febrile neutropenic patients
    Marshall, E
    Smith, DB
    O'Reilly, SM
    Murray, A
    Kelly, V
    Clark, PI
    SUPPORTIVE CARE IN CANCER, 2000, 8 (03) : 198 - 202
  • [9] Low-dose continuous-infusion ceftazidime monotherapy in low-risk febrile neutropenic patients
    E. Marshall
    D. B. Smith
    S. M. O'Reilly
    A. Murray
    V. Kelly
    P. I. Clark
    Supportive Care in Cancer, 2000, 8 : 198 - 202
  • [10] Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients
    Luciano de Souza Viana
    José Carlos Serufo
    Manoel Otávio da Costa Rocha
    Renato Nogueira Costa
    Roberto Carlos Duarte
    Supportive Care in Cancer, 2008, 16 : 841 - 846